December2016
Home
»
Allegiant Rx News
Allegiant Rx News
12-29-2016
RxWIRE Newsletter – December 29, 2017
On April 26, an FDA advisory committee voted 7-6 that the exon-skipping drug eteplirsen for Duchenne muscular dystrophy (DMD) failed to meet the standards needed for accelerated approval.
Read More
12-22-2016
RxWIRE Newsletter – December 22, 2016
We won't surprise anyone by saying that Topic No. 1 in pharma this year was drug pricing. We'll give you one guess as to whether 2017 will be more of the same.
Read More
12-15-2016
RxWIRE Newsletter – December 15, 2016
The financial future of pharmacy benefit managers is uncertain as payers, legislators and regulators focus on rising drug prices, according to Moody's Investors Service.
Read More
12-08-2016
RxWIRE Newsletter – December 8, 2016
That didn't take long. Less than a week since Allergan CEO Brent Saunders implored pharma to take the initiative to defuse a public debate on drug pricing, Novo Nordisk has become the second player to make a cost pledge.
Read More
